Acutus Medical Has Been Granted European Patent Number EP3043701 Titled "Devices And Methods For Determination Of Electrical Dipole Densities On A Cardiac Surface (And Methods For Diagnosing Tissue Health)".
Portfolio Pulse from Benzinga Newsdesk
Acutus Medical, a company specializing in electrophysiology, has been granted a European patent, EP3043701, for its technology related to diagnosing cardiac tissue health. The patent covers devices and methods for determining electrical dipole densities on a cardiac surface, which is crucial for diagnosing tissue health.
January 24, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acutus Medical (AFIB) has been granted a European patent for its cardiac diagnostic technology, which may enhance its product portfolio and competitive edge in the European market.
The granting of a European patent to Acutus Medical for its cardiac diagnostic technology is likely to have a positive impact on the company's stock price in the short term. This patent can protect the company's intellectual property, potentially reduce competition, and open up new market opportunities in Europe. Investors may view this as a sign of innovation and growth potential, which can lead to increased investor confidence and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100